Hjem
Per Eystein Lønnings bilde

Per Eystein Lønning

Professor
  • E-postPer.Lonning@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 27
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen.  Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift. 

Vitenskapelig artikkel
  • Vis forfatter(e) (2013). Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 12 sider.
  • Vis forfatter(e) (2013). Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis. 867-876.
  • Vis forfatter(e) (2013). Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 12 sider.
  • Vis forfatter(e) (2013). Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 2790-2797.
  • Vis forfatter(e) (2013). Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE.
  • Vis forfatter(e) (2012). Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic Advances in Medical Oncology.
  • Vis forfatter(e) (2012). Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 13 sider.
  • Vis forfatter(e) (2012). Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 6 sider.
  • Vis forfatter(e) (2011). Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 9-12.
  • Vis forfatter(e) (2011). Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription.
  • Vis forfatter(e) (2010). MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 2127-2133.
  • Vis forfatter(e) (2010). Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • Vis forfatter(e) (2010). Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • Vis forfatter(e) (2010). Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Molecular Cancer. 13 sider.
  • Vis forfatter(e) (2010). Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • Vis forfatter(e) (2010). Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • Vis forfatter(e) (2010). Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • Vis forfatter(e) (2010). DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 sider.
  • Vis forfatter(e) (2010). Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • Vis forfatter(e) (2010). Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • Vis forfatter(e) (2009). Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • Vis forfatter(e) (2009). Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • Vis forfatter(e) (2009). Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • Vis forfatter(e) (2009). Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • Vis forfatter(e) (2009). Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • Vis forfatter(e) (2009). A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • Vis forfatter(e) (2008). The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Vis forfatter(e) (2008). Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • Vis forfatter(e) (2008). Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • Vis forfatter(e) (2008). Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • Vis forfatter(e) (2008). Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • Vis forfatter(e) (2008). Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • Vis forfatter(e) (2008). CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 15 sider.
  • Vis forfatter(e) (2008). Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • Vis forfatter(e) (2008). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • Vis forfatter(e) (2008). An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
  • Vis forfatter(e) (2007). Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • Vis forfatter(e) (2007). Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • Vis forfatter(e) (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • Vis forfatter(e) (2007). Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
  • Vis forfatter(e) (2007). Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
  • Vis forfatter(e) (2007). Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • Vis forfatter(e) (2007). Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • Vis forfatter(e) (2007). Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • Vis forfatter(e) (2007). ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • Vis forfatter(e) (2006). Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • Vis forfatter(e) (2006). The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • Vis forfatter(e) (2006). Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • Vis forfatter(e) (2006). Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • Vis forfatter(e) (2006). Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • Vis forfatter(e) (2006). Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • Vis forfatter(e) (2006). Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6 sider.
  • Vis forfatter(e) (2006). Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • Vis forfatter(e) (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Vis forfatter(e) (2006). Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • Vis forfatter(e) (2006). A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • Vis forfatter(e) (2005). Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 525-530.
  • Vis forfatter(e) (2005). Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • Vis forfatter(e) (2005). Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • Vis forfatter(e) (2005). Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 878s-883s.
  • Vis forfatter(e) (2005). Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • Vis forfatter(e) (2005). Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
  • Vis forfatter(e) (2005). Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • Vis forfatter(e) (2005). Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • Vis forfatter(e) (2004). Understanding chemoresistance- the ultimate challenge in cancer therapy. Breast Cancer Online.
  • Vis forfatter(e) (2004). PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • Vis forfatter(e) (2004). Oestrogen suppression; lessons from clinical studies. Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism. 33-45.
  • Vis forfatter(e) (2004). Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • Vis forfatter(e) (2004). Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • Vis forfatter(e) (2004). Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clinical Cancer Research. 3438-3443.
  • Vis forfatter(e) (2004). Genes causing inherited cancer as beacons to identify the mechanism of chemoresistance. Trends in Molecular Medicine. 113-118.
  • Vis forfatter(e) (2004). Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind study. New England Journal of Medicine. 1081-1092.
  • Vis forfatter(e) (2004). Cell-type specific responses to chemotherapeutics in breast cancer. Cancer Research. 4218-4226.
  • Vis forfatter(e) (2004). Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 8535-8544.
  • Vis forfatter(e) (2004). Alternative splicing and mutation status of CHEK2 in stag III breast cancer. Oncogene. 8535-8544.
  • Vis forfatter(e) (2003). X chromosome inactivation in cervical cancer patients. Cancer Genetics and Cytogenetics. 73-76.
  • Vis forfatter(e) (2003). TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) (2003). TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) (2003). Study of suboptimum treatment response: lessons from breast cancer. The Lancet. 177-185.
  • Vis forfatter(e) (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • Vis forfatter(e) (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • Vis forfatter(e) (2003). Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) (2003). Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) (2003). Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology. 23-32.
  • Vis forfatter(e) (2003). Development of aromatase inhibitors and their pharmacologic profile. American Journal of Clinical Oncology. S3-S8.
  • Vis forfatter(e) (2003). Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clinical Pharmacokinetics. 619-631.
  • Vis forfatter(e) (2002). Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • Vis forfatter(e) (2002). Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. American Journal of Oncology Review. 99-102.
  • Vis forfatter(e) (2002). Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology. 751-757.
  • Vis forfatter(e) (2002). Aromatase inhibitors and inactivators for breast cancer therapy. Drugs & Aging. 277-298.
  • Vis forfatter(e) (2002). Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Human Gene Therapy. 1115-1125.
  • Vis forfatter(e) (2001). The insulinlike growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism (JCEM). 227-233.
  • Vis forfatter(e) (2001). The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism (JCEM). 227-233.
  • Vis forfatter(e) (2001). Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow`s Challenges. Clinical Breast Cancer. 297-308.
  • Vis forfatter(e) (2001). Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. British Journal of Cancer. 74-77.
  • Vis forfatter(e) (2001). Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • Vis forfatter(e) (2001). Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • Vis forfatter(e) (2001). Microarrays in primary breast cancer -lessons from chemotherapy studies. Endocrine-Related Cancer. 259-263.
  • Vis forfatter(e) (2001). Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research. 1230-1236.
  • Vis forfatter(e) (2001). Influence of TP53 gene alterations and cErbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research. 2505-2512.
  • Vis forfatter(e) (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment. 111-116.
  • Vis forfatter(e) (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 10869-10874.
  • Vis forfatter(e) (2001). Exemestane: a review of its clinical efficacy and safety. Breast. 198-208.
  • Vis forfatter(e) (2001). Alterations in the insulin-like growth factor-system during treatment with diethylstilbestrol in patients with metastatic breast cancer. British Journal of Cancer. 147-151.
  • Vis forfatter(e) (2000). Screening breast cancer patients for Norwegian ATM mutations. British Journal of Cancer. British Journal of Cancer. 1650-53.
  • Vis forfatter(e) (2000). Molecular portraits of human breast tumours. Nature. 747-52.
  • Vis forfatter(e) (2000). Genetic variants of CYP19 (arometase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) (2000). Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) (1999). CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Research. 2825-2828.
  • Vis forfatter(e) (1999). CYP 17 and breast cancer risk; the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
  • Vis forfatter(e) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) (1998). Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • Vis forfatter(e) (1998). Microencapsulated Octreotide in Advanced Gastrointestinal and Pancreatic Cancer: a Phase I Study. British Journal of Cancer. 14-20.
  • Vis forfatter(e) (1998). Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Vis forfatter(e) (1998). Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Vis forfatter(e) (1998). Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • Vis forfatter(e) (1998). Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Vis forfatter(e) (1998). Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Vis forfatter(e) (1998). Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
  • Vis forfatter(e) (1997). Subgroups of TP53 mutations may predict clinical behaviour and therapy response in breast and ovary cancer patients. Breast and Ovarian Cancer: Molecular Markers of Risk: Progression and new Therapeutic strategies, Pisa, Italy..
  • Vis forfatter(e) (1997). Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • Vis forfatter(e) (1997). Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • Vis forfatter(e) (1997). Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • Vis forfatter(e) (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) (1997). Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Vis forfatter(e) (1997). Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Vis forfatter(e) (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) (1997). Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • Vis forfatter(e) (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1997). Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1996). Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
  • Vis forfatter(e) (1996). Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) (1996). Specific p53 mutations are associated with de novo ressistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) (1996). Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • Vis forfatter(e) (1996). Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • Vis forfatter(e) (1996). Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • Vis forfatter(e) (1996). Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Vis forfatter(e) (1996). Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Vis forfatter(e) (1996). Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism (JCEM). 2216-2221.
  • Vis forfatter(e) (1996). Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • Vis forfatter(e) (1996). Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
  • Vis forfatter(e) (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Vis forfatter(e) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) (1995). Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 193-195.
  • Vis forfatter(e) (1995). Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • Vis forfatter(e) (1994). Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. European Journal of Cancer. 106-111.
  • Vis forfatter(e) (1993). Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • Vis forfatter(e) (1993). Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Vis forfatter(e) (1993). Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Vis forfatter(e) (1993). Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
Vitenskapelig foredrag
  • Vis forfatter(e) (2012). Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • Vis forfatter(e) (2011). GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • Vis forfatter(e) (2010). Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • Vis forfatter(e) (2010). Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • Vis forfatter(e) (1999). Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • Vis forfatter(e) (1999). Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • Vis forfatter(e) (1995). A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • Vis forfatter(e) (1994). Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • Vis forfatter(e) (1994). Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) (2004). Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Sammendrag/abstract
  • Vis forfatter(e) (2010). Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • Vis forfatter(e) (2009). Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • Vis forfatter(e) (2009). DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • Vis forfatter(e) (2008). ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • Vis forfatter(e) (2008). Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • Vis forfatter(e) (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Vis forfatter(e) (2007). Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • Vis forfatter(e) (2007). Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • Vis forfatter(e) (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Vis forfatter(e) (2005). The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2019). Constitutional mosaic epimutations - A hidden cause of cancer? Cell stress. 118-135.
  • Vis forfatter(e) (2016). Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. Journal of Clinical Oncology. 1580-1583.
  • Vis forfatter(e) (2015). Estradiol measurement in translational studies of breast cancer. Steroids. 26-31.
  • Vis forfatter(e) (2014). The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 681-700.
  • Vis forfatter(e) (2013). Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 5315-5330.
  • Vis forfatter(e) (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. R183-R201.
  • Vis forfatter(e) (2012). P53 and its molecular basis to chemoresistance in breast cancer. Expert opinion on therapeutic targets. S23-S30.
  • Vis forfatter(e) (2011). The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology. 503-514.
  • Vis forfatter(e) (2011). Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clinical Cancer Research. 4948-4958.
  • Vis forfatter(e) (2010). Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 1825-1836.
  • Vis forfatter(e) (2010). Molecular basis for therapy resistance. Molecular Oncology. 284-300.
  • Vis forfatter(e) (2009). Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer. 527-535.
  • Vis forfatter(e) (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Vis forfatter(e) (2009). Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncologica. 1092-1101.
  • Vis forfatter(e) (2008). Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs. 723-739.
  • Vis forfatter(e) (2007). Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 1293-1306.
  • Vis forfatter(e) (2006). Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology. 53-61.
  • Vis forfatter(e) (2004). Aromatase inhibitors in breast cancer. Endocrine-Related Cancer. 179-189.

Se fullstendig oversikt over publikasjoner i CRIStin.

Kompetansefelt